IMDX - Insight Molecular Diagnostics Inc. Common Stock
| Day | 1m | 10m | 60m | PreMarket | Market | AfterHours | Gap |
|---|---|---|---|---|---|---|---|
| 4.06 0.23 (5.67%) | --- | --- | --- | --- | 0.24 (5.91%) | -0.01 (-0.23%) | -0.01 (-0.23%) |
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx.
Category:
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Market Period:
Closed
Earnings & Ratios
- Basic EPS:
- -0.3
- Diluted EPS:
- -0.3
- Basic P/E:
- -14.3007
- Diluted P/E:
- -14.3007
- RSI(14) 1m:
- 0.0
- VWAP:
- 4.3
- RVol:
Events
| Period | Kind | Movement | Occurred At |
|---|